Back to results
US 2020/0400681 A1Published application
Method for quantitatively determining a therapeutic tnf-alpha inhibitor
AssigneeSiemens Healthcare Diagnostics Products GmbH
InventorsHarald ALTHAUS, Thorsten KELLER
Life of this patent
Estimating the term…
Abstract
The invention is in the field of in vitro diagnostics and relates to a method for quantitatively determining therapeutic TNF-alpha inhibitors.
Claims20
A method for quantitatively determining a therapeutic TNF-alpha inhibitor in a sample, the method comprising the steps of:
- a) providing a reaction mixture by contacting the sample
- i. with isolated, free TNF-alpha protein and then
- ii. with a first TNF-alpha binding partner;
- b) determining the amount of a complex which forms in the reaction mixture and is composed of TNF-alpha protein and the first TNF-alpha binding partner;
- and
- c) determining the amount of the therapeutic TNF-alpha inhibitor in the sample by comparing the amount of the complex composed of TNF-alpha protein and the first TNF-alpha binding partner determined in the reaction mixture with amounts of a complex composed of TNF-alpha protein and the first TNF-alpha binding partner in reaction mixtures containing samples having known concentrations of a TNF-alpha binding partner.
3 more elements
An assay kit for use in a method for quantitatively determining a therapeutic TNF-alpha inhibitor in a sample, which contains the following components:
- a) a first vessel containing a reagent, the reagent containing 50 μg-2 mg/L isolated, free TNF-alpha protein;
- and
- b) a second vessel containing a first TNF-alpha binding partner.
Dependencies are inferred from the claim text.